April 2000 Cover
|
 |
Researchers from Bristol-Myers Squibb said they are developing a once-daily drug for AIDS. Current protease inhibitor regimens require six to 20 pills a day, taken throughout the day.
A simpler dosing schedule would be easier for patients to take and could thus help prevent the development of resistant HIV strains that develop when patients only take some of their medications.
The small study of 93 patients found that the new drug, combined with Videx and Zerit, worked as effectively as other combination therapies in reducing HIV loads in patients' bloodstreams to
undetectable levels.
In other news, Merck & Co. reported that it has halted a study of a twice daily drug known as MK-944A because laboratory rodents who received the drug developed a kidney toxicity.
Editor's Note: from the Wall Street Journal
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
